scholarly journals Polymorphism in genes encoding xenobiotic-metabolizing enzymes (GSTM1 and GSTT1) and the risk of asthma onset in Moldovan and other ethnic groups: a meta-analysis

2014 ◽  
Vol 11 (1) ◽  
pp. 39-44
Author(s):  
L V Vasilos ◽  
O N Kyrstya ◽  
T E Ivashchenko ◽  
A N Kozhokaru ◽  
M V Aseyev ◽  
...  
Keyword(s):  
Ethnic Groups ◽  
Meta Analysis ◽  
Cumulative Risk ◽  
Fold Increase ◽  
Published Data ◽  
Metabolizing Enzymes ◽  
Xenobiotic Metabolizing Enzymes ◽  
Increased Risk ◽  
Genes Encoding ◽  
Risk Of Disease

Background. The aim of the study was to examine the association of the risk of asthma onset with polymorphisms in genes encoding proteins xenobiotic metabolizing enzymes (GSTT1 and GSTM1) in Moldovans and other ethnic groups using the meta-analysis method. Methods. A meta-analysis of the association of genetic polymorphism of GSTT1 and GSTM1 genes and the risk of asthma development in 180 Moldovan subjects in comparison with published data on various ethnogeographical affiliations was performed. Results. The meta-analysis results were based on sixteen studies which included a total number of 3873 patients and 4863 healthy individuals. The meta-analysis showed an increased risk of disease development in subjects who are carriers of the GSTM1 null genotype (odds ratio of the cumulative risk was 1,29; 95% CI 1,09-1,54), whereas the GSTT1 0/0 genotype was associated with a 1,32 fold increase of the cumulative risk of asthma onset (95% CI 0,99-1,75). Conclusion. The obtained results suggest that the risk of asthma development is associated with the deletion polymorphism in genes encoding proteins xenobiotic metabolizing enzymes (GSTT1 and GSTM1), but the mechanisms of the disease also depend on the gene-by-gene and gene-environment interactions.

Edoxaban versus placebo, aspirin, or aspirin plus clopidogrel for stroke prevention in atrial fibrillation

2015 ◽  
Vol 114 (08) ◽  
pp. 403-409 ◽  
Author(s):  
Lars Rasmussen ◽  
Torben Larsen ◽  
Andrew Blann ◽  
Flemming Skjøth ◽  
Gregory Lip
Keyword(s):  
Atrial Fibrillation ◽  
Clinical Trial ◽  
Real World ◽  
Meta Analysis ◽  
Oral Anticoagulants ◽  
Published Data ◽  
Real World Data ◽  
Once Daily ◽  
Increased Risk ◽  
Reduced Risk

SummaryAs non-valvular atrial fibrillation (AF) brings a risk of stroke, oral anticoagulants (OAC) are recommended. In ‘real world’ clinical practice, many patients (who may be, or perceived to be, intolerant of OACs) are either untreated or are treated with anti-platelet agents. We hypothesised that edoxaban has a better net clinical benefit (NCB, balancing the reduction in stroke risk vs increased risk of haemorrhage) than no treatment or anti-platelet agents. We performed a network meta-analysis of published data from 24 studies of 203,394 AF patients to indirectly compare edoxaban with aspirin alone, aspirin plus clopidogrel, and placebo. Edoxaban 30 mg once daily significantly reduced the risk of all stroke, ischaemic stroke and mortality compared to placebo and aspirin. Compared to aspirin plus clopidogrel, there was a lower risk of intra-cranial haemorrhage (ICH). Edoxaban 60 mg once-daily had a reduced risk of any stroke and systemic embolism compared to placebo, aspirin, and aspirin plus clopidogrel. Mortality rates for both edoxaban doses were estimated to be lower compared to any anti-platelet, and significantly lower compared to placebo. With overall reduced risk of ischemic stroke and ICH, both edoxaban doses bring a NCB of mean (SD) 1.68 (0.15) saved events per 100 patients per year compared to anti-platelet drugs in a clinical trial population. The NCB was demonstrated to be lower, at 0.77 (0.12) events saved (p< 0.01) when modeled to data from a ‘real world’ cohort of AF patients. In conclusion, edoxaban is likely to provide even better protection from stroke and ICH than placebo, aspirin alone, or aspirin plus clopidogrel in both clinical trial populations and unselected community populations. Both edoxaban doses would also bring a positive NCB compared to anti-platelet drugs or placebo/non-treatment based on ‘real world’ data.Note: The review process for this paper was fully handled by Christian Weber, Editor in Chief.

Urinary Tract Infections and the Uncircumcised State: An Update

1993 ◽  
Vol 32 (3) ◽  
pp. 130-134 ◽  
Author(s):  
Thomas E. Wiswell ◽  
Wayne E. Hachey
Keyword(s):  
Urinary Tract ◽  
Urinary Tract Infections ◽  
Meta Analysis ◽  
Fold Increase ◽  
First Year ◽  
Us Army ◽  
Increased Risk ◽  
Army Hospitals ◽  
Tract Infections ◽  
First Year Of Life

In a two-part study of the circumcision status of boys with urinary tract infections (UTIs), we reviewed the occurrence of UTIs in 209,399 infants born in US Army hospitals worldwide from 1985 to 1990. During the first year of life, 1,046 (0.5%: 550 girls and 496 boys) were hospitalized for UTIs. Noncircumcised male infants had a 10-fold greater incidence of infection than did circumcised male infants. The frequency rate of circumcision rose significantly, from 70.3% to 80.2%, during the study period. Among uncircumcised boys younger than 3 months with UTIs, 23% had concomitant bacteremia involving the same organism. The second part of the study consisted of a meta-analysis of all nine previous reports on the circumcision status of boys with UTIs. These studies revealed a fivefold to 89-fold increased risk of infection in uncircumcised boys; the combined data yielded a 12-fold increase in UTIs in this population. Parents should be told of the lower risk of UTIs for circumcised boys during informed-consent counseling.

Outcomes of Medication Misadventure Among People With Cognitive Impairment or Dementia: A Systematic Review and Meta-analysis

2020 ◽  
pp. 106002802094912
Author(s):  
Anum Saqib Zaidi ◽  
Gregory M. Peterson ◽  
Luke R.E. Bereznicki ◽  
Colin M. Curtain ◽  
Mohammed Salahudeen
Keyword(s):  
Systematic Review ◽  
Cognitive Impairment ◽  
Adverse Drug Events ◽  
Data Extraction ◽  
Meta Analysis ◽  
Published Data ◽  
Potentially Inappropriate Medications ◽  
Cochrane Central Register ◽  
Increased Risk ◽  
Meta Analyses

Objective: To investigate mortality and hospitalization outcomes associated with medication misadventure (including medication errors [MEs], such as the use of potentially inappropriate medications [PIMs], and adverse drug events [ADEs]) among people with cognitive impairment or dementia. Data Sources: Ovid MEDLINE, Ovid EMBASE, Ovid International Pharmaceutical Abstracts, Cumulative Index to Nursing and Allied Health Literature, and Cochrane Central Register of Controlled Trials were searched from inception to December 2019. Study Selection and Data Extraction: Relevant studies using any study design were included. Reviewers independently performed critical appraisal and extracted relevant data. Data Synthesis: The systematic review included 10 studies that reported the outcomes of mortality or hospitalization associated with medication misadventure, including PIMs (n=5), ADEs (n=2), a combination of MEs and ADEs (n=2), and drug interactions (n=1). Five studies examining the association between PIMs and mortality/hospitalization were included in the meta-analyses. Exposure to PIMs was not associated with either mortality (odds ratio [OR]=1.36; 95%CI=0.79-2.35) or hospitalization (OR=1.02; 95%CI=0.83-1.26). In contrast, single studies indicated that ADEs with cholinesterase inhibitors were associated with mortality and hospitalization. Relevance to Patient Care and Clinical Practice: Individuals with cognitive impairment or dementia are at increased risk of medication misadventure; based on relatively limited published data, this does not necessarily translate to increased mortality and hospitalization. Conclusions: Overall, medication misadventure was not associated with mortality or hospitalization in people with cognitive impairment or dementia, noting the limited number of studies, difficulty in controlling potential confounding variables, and that most studies focus on PIMs.

scholarly journals Applicability of logistic regression with sum-to-zero constraint parameterization in risk assessment for parotid malignancy

2019 ◽  
Author(s):  
Shari Messinger Cayetano ◽  
Kaming Lo ◽  
Christopher Fundakowski ◽  
Zoukaa Sargi
Keyword(s):  
Logistic Regression ◽  
Odds Ratio ◽  
Fine Needle Aspiration Biopsy ◽  
Clinical Presentation ◽  
Fold Increase ◽  
Needle Aspiration ◽  
Reference Cell ◽  
Model Parameterization ◽  
Increased Risk ◽  
Risk Of Disease

Abstract Background Investigative interest is often to determine how results from a diagnostic tool change the patient’s risk of disease with respect to the overall(naïve) risk at clinical presentation. Logistic regression is popular for data analysis for this type of investigation. However, standard approach, which uses reference cell coding, may not be informative in this setting. This is because this approach compares the risk between two distinct groups.Methods We considered weighted and unweighted approaches to model parameterization using deviation from means coding for assessing the risk of parotid malignancy, comparing patients with indeterminate fine-needle aspiration biopsy(FNAB) results with the general(naïve) risk among all presenting patients. Results from deviation from means coding and standard reference cell coding were compared.Results Unweighted coding estimates a two-fold increase in the odds of malignancy with an indeterminate FNAB result compared to the naïve odds at clinical presentation (Odds ratio(OR): 1.97 [95% Confidence Interval(CI): 1.34–2.90], P=0.0006). The weighted approach estimates increased risk (OR: 2.38 [95% CI: 1.45 – 3.89], P=0.0006), more accurately representing the naïve risk at presentation based on the direction of sample imbalance in the study. Using standard reference cell coding, an indeterminate result has a higher risk compared to a negative result, but this does not inform us about the risk with respect to that inherent at clinical presentation.Conclusions Depending on the investigative interest, it is important to adopt the appropriate coding methodology when logistic regression is applied. In addition, a weighted approach should be considered to account for sample imbalance.

scholarly journals The association of MTHFR A1298C polymorphism with cervical cancer: An Updated Meta-Analysis Involving 2835 Subjects

2020 ◽  
Author(s):  
Chunyan Mu ◽  
Zhongcheng Wang ◽  
Yue Wang ◽  
Ying Li ◽  
Bing Gu ◽  
...  
Keyword(s):  
Cervical Cancer ◽  
Fixed Effects ◽  
Cancer Susceptibility ◽  
Meta Analysis ◽  
Recessive Model ◽  
Cochrane Library ◽  
Published Data ◽  
Mthfr A1298c ◽  
Increased Risk ◽  
A1298c Polymorphism

Abstract Background Published data have reported the relationships between MTHFR A1298C polymorphisms and cervical cancer susceptibility. However, the conclusions of these findings lack consistency.Methods A comprehensive literature search was performed using Web of Science, PubMed, EMBASE, Cochrane library, Wan Fang and CNKI databases. The pooled odds ratios (ORs) with 95% confidence intervals (CIs) were used to evaluate the correlation of MTHFR A1298C polymorphism and cervical cancer risk. Fixed-effects or random effects models was adopted according to heterogeneity test.Results A total of nine studies (1145 cases and 1690 controls) were included in this meta-analysis. Pooled data revealed that MTHFR A1298C polymorphism was significantly associated with an increased risk of cervical cancer in the allele model (P=0.028); the recessive model (P=0.028); and the heterozygous model (P=0.031).Conclusions Our results revealed that MTHFR A1298C polymorphism was associated with risk of cervical cancer.

Polymorphisms in genes encoding drugs and xenobiotic metabolizing enzymes in a Brazilian population

Biomarkers ◽  
2009 ◽  
Vol 14 (2) ◽  
pp. 111-117 ◽  
Author(s):  
Vanessa Da Silva Silveira ◽  
Renata Canalle ◽  
Carlos Alberto Scrideli ◽  
Rosane Gomes de Paula Queiroz ◽  
Luiz Gonzaga Tone
Keyword(s):  
Brazilian Population ◽  
Metabolizing Enzymes ◽  
Xenobiotic Metabolizing Enzymes ◽  
Genes Encoding

Overweight, Obesity and Endometrial Cancer Risk: Results from a Systematic Review and Meta-Analysis

2014 ◽  
Vol 29 (1) ◽  
pp. e21-e29 ◽  
Author(s):  
Yuanyuan Zhang ◽  
Huaizhen Liu ◽  
Shengjie Yang ◽  
Jinjun Zhang ◽  
Liwei Qian ◽  
...  
Keyword(s):  
Body Mass Index ◽  
Endometrial Cancer ◽  
Cancer Risk ◽  
Body Mass ◽  
Meta Analysis ◽  
Overweight And Obesity ◽  
Age At Menarche ◽  
Published Data ◽  
Endometrial Cancer Risk ◽  
Increased Risk

Aim Findings from recent studies suggest that obesity may be associated with an increased risk of endometrial cancer, but several earlier studies were less conclusive. Here we strive to estimate this relationship in a meta-analysis of published data. Methods We searched Pubmed and Embase for studies on body mass index and the risk of endometrial cancer, published from 1989 to 2011. Data were independently extracted and analyzed using random or fixed effects meta-analysis depending on the degree of heterogeneity. Results Seven cohort studies and 11 case-control studies were included in the meta-analysis. Overall, the conditions of excess body weight ([EBW] defined as body mass index [BMI] ≥25 kg/m2), obesity (BMI ≥30 kg/m2) and overweight (25< BMI <30 kg/m2) were associated with an increased risk of endometrial cancer (relative risk [RR] for EBW=1.62, 95% confidence interval [CI], 1.39-1.89; for obesity RR=2.54, 95% CI, 2.11-3.06; for overweight RR=1.32, 95% CI, 1.16-1.50). Subgroup analyses showed that the positive associations were independent of study design, geographic locations, self-reported BMI, alcohol use, smoking habit, history of diabetes, hormone therapy, age at menarche, age at menopause, parity, and age at first full term pregnancy. However, there was no statistically significant association between EBW and endometrial cancer risk for measured BMI (for EBW RR=1.29, 95% CI, 0.66-2.53). Conclusions The findings from this meta-analysis strongly support that the conditions of EBW, overweight, and obesity are all associated with an increased risk of endometrial cancer. Also, the strength of the association increases with increasing BMI.

Sign in / Sign up

Export Citation Format

Share Document